HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $20 price target.
February 20, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals maintains a Buy rating and a $20 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards RVPH, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100